Aura Biosciences, Inc. Financing Cash Flow
Aura Biosciences, Inc. (AURA) reported Financing Cash Flow of $242.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- Aura Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $241.75M, a 245.71% increase year-over-year.
- Aura Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $300.00K, a 212.50% increase year-over-year.
- Aura Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $2.77M, a 409.58% increase year-over-year.
- Aura Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $4.36M, a 509.36% increase year-over-year.
- Aura Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $77.16M, a 4737.30% increase from fiscal 2024.
- Aura Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $1.59M, a 98.36% decline from fiscal 2023.
- Aura Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $97.29M, a 1.74% increase from fiscal 2022.
- Aura Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $95.63M, a 42.48% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $241.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $242.05M 10-Q · filed 2026-08-11 | $244.82M derived: sum of 3 quarters · filed 2026-08-11 | $249.18M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $300.00K 10-Q · filed 2026-05-11 | $3.07M derived: sum of 2 quarters · filed 2026-05-11 | $7.43M derived: sum of 3 quarters · filed 2026-05-11 | $77.36M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $7.13M derived: sum of 2 quarters · filed 2026-03-30 | $77.06M derived: sum of 3 quarters · filed 2026-08-11 | $77.16M 10-K · filed 2026-03-30 |
| 2025-09-30 | $4.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $74.29M derived: sum of 2 quarters · filed 2026-08-11 | $74.39M 10-Q · filed 2025-11-13 | $74.93M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $69.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $70.03M 10-Q · filed 2026-08-11 | $70.57M derived: sum of 3 quarters · filed 2026-08-11 | $71.28M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $96.00K 10-Q · filed 2026-05-11 | $639.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.35M derived: sum of 3 quarters · filed 2026-05-11 | $1.44M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $543.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.26M derived: sum of 2 quarters · filed 2026-03-30 | $1.34M derived: sum of 3 quarters · filed 2026-03-30 | $1.59M 10-K · filed 2026-03-30 |
| 2024-09-30 | $716.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $799.00K derived: sum of 2 quarters · filed 2025-11-13 | $1.05M 10-Q · filed 2025-11-13 | $94.04M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $83.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $336.00K 10-Q · filed 2025-08-13 | $93.32M derived: sum of 3 quarters · filed 2025-08-13 | $94.95M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $253.00K 10-Q · filed 2025-05-15 | $93.24M derived: sum of 2 quarters · filed 2025-05-15 | $94.86M derived: sum of 3 quarters · filed 2025-05-15 | $97.34M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $92.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $94.61M derived: sum of 2 quarters · filed 2025-03-24 | $97.09M derived: sum of 3 quarters · filed 2025-03-24 | $97.29M 10-K · filed 2025-03-24 |
| 2023-09-30 | $1.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $4.10M derived: sum of 2 quarters · filed 2024-11-12 | $4.30M 10-Q · filed 2024-11-12 | $99.50M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.68M 10-Q · filed 2024-08-08 | $97.88M derived: sum of 3 quarters · filed 2024-08-08 | $97.98M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $201.00K 10-Q · filed 2024-05-09 | $95.40M derived: sum of 2 quarters · filed 2024-05-09 | $95.50M derived: sum of 3 quarters · filed 2024-05-09 | $95.81M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $95.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $95.30M derived: sum of 2 quarters · filed 2024-03-27 | $95.61M derived: sum of 3 quarters · filed 2024-03-27 | $95.63M 10-K · filed 2024-03-27 |
| 2022-09-30 | $104.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $413.00K derived: sum of 2 quarters · filed 2023-11-09 | $430.00K 10-Q · filed 2023-11-09 | $80.57M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $309.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $326.00K 10-Q · filed 2023-08-09 | $80.47M derived: sum of 3 quarters · filed 2023-08-09 | $79.35M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $17.00K 10-Q · filed 2023-05-11 | $80.16M derived: sum of 2 quarters · filed 2023-05-11 | $79.04M derived: sum of 3 quarters · filed 2023-05-11 | $78.79M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $80.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $79.03M derived: sum of 2 quarters · filed 2023-03-15 | $78.77M derived: sum of 3 quarters · filed 2023-03-15 | $166.26M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$1.37M derived: sum of 2 quarters · filed 2022-11-10 | $86.12M 10-Q · filed 2022-11-10 | $91.25M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$256.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $87.23M 10-Q · filed 2022-08-11 | $92.37M derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $87.49M 10-Q · filed 2022-05-12 | $92.62M derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $5.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $10.04M 10-K · filed 2022-03-23 | ||
| 2020-09-30 | $4.90M 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |